Hasil Pencarian - Zhuo‐Miao Ye

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer

    Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer oleh Zhuo-Miao Ye, Zhuo-Miao Ye, Zhe Xu, Fan-Yuan Zeng, Zi-Qing Tang, Qin Zhou, Qin Zhou

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer

    Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer oleh Zhuo-miao Ye, Zhe Xu, Huan Li, Qian Li

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma

    Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma oleh Zhuo-miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, Huan Li

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    m6A-related lncRNA-based immune infiltration characteristic analysis and prognostic model for colonic adenocarcinoma

    m6A-related lncRNA-based immune infiltration characteristic analysis and prognostic model for colonic adenocarcinoma oleh Hao-lun Wang, Zhuo-miao Ye, Zi-yun He, Lu Huang, Zhi-hui Liu

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China

    Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China oleh Zhe Xu, Zhuo‐miao Ye, Yu‐kai Tang, Dong‐feng Deng, Qin Zhou, Man Fang, Ying‐ying Zhang, Xiang‐ping Li

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer

    Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer oleh Zhuo‐Miao Ye, Zhe Xu, Hao‐Lun Wang, Ying‐Yuan Wang, Ze‐Chang Chen, Qin Zhou, Xiang‐Ping Li, Ying‐Ying Zhang

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: